{"nctId":"NCT00811473","briefTitle":"Pediatric Bipolar Depression","startDateStruct":{"date":"2009-01"},"conditions":["Bipolar Depression"],"count":193,"armGroups":[{"label":"Quetiapine XR","type":"EXPERIMENTAL","interventionNames":["Drug: Quetiapine XR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Quetiapine XR","otherNames":["Seroquel XR"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent by one or both parents or legal guardian and written assent by the patients before any study procedures are performed.\n* The patient must have a documented clinical diagnosis for bipolar I or bipolar II disorder, and including current episode depressed.\n* Patients are required to be in outpatient status at the enrollment and randomization visits and believed likely to remain an outpatient for the duration of the study.\n* Patients must be able to swallow the study medication tablets.\n\nExclusion Criteria:\n\n* The patient must not have been diagnosed with Tourette's Disorder, Obsessive-Compulsive Disorder, acute Post-traumatic Stress Disorder, Panic Disorder, Autistic Disorder and/or Asperger's Disorder.\n* Patient can not have a history of non-response to an adequate treatment to more than 2 antidepressants during the current episode.\n* The patient must not have received electroconvulsive therapy (ECT) within 30 days before participating in the study.\n* Patients who in your doctors judgement pose a current suicidal or homicidal risk.","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Children Depression Rating Scale, Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57)","description":"Severity of depression in children and adolescents was calculated based on the 17-item CDRS-R scale (3 items scored from 1-5 and 14 items scored from 1-7, with higher scores indicating more severe depression). The 17 item scores are summed to give the total score (total score range 17-113).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.6","spread":"1.65"},{"groupId":"OG001","value":"-27.3","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Reaching Remission Where Remission is Defined as CDRS-R Total Score ≤28 at Final Assessment (Day 57).","description":"The number of patients with remission from Days 8 to 57 was calculated. The CDRS-R is a 17-item scale with 3 items scored from 1-5 and 14 items scored from 1-7, where higher scores indicating more severe depression. The 17 item scores are summed to give the total score (total score range 17-113).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients With the Response, Where Response is Defined as ≥50% Reduction From Baseline to Final Assessment (Day 57) in CDRS-R Total Score","description":"The number of patients reaching response from Days 8 to 57 was calculated. The CDRS-R is a 17-item scale with 3 items scored from 1-5 and 14 items scored from 1-7, where higher scores indicating more severe depression. The 17 item scores are summed to give the total score (total score range 17-113).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Final Assessment (Day 57) in the CGI-BP-S","description":"The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.2","spread":"0.15"},{"groupId":"OG001","value":"-1.35","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"CGI-BP-C Score at Final Assessment (Day 57)","description":"The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). CGI-BP-C scores \\>4 indicate worsening, while scores \\<4 indicate improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.15"},{"groupId":"OG001","value":"2.6","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Patients at Final Assessment (Day 57) With Improvement of Overall Bipolar Illness","description":"The proportion of patients with improvement of overall bipolar illness at Day 57 was calculated. Improvement defined as a CGI-BP-C of \"Much\" or \"Very much\" improved in overall bipolar illness assessment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.522","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Headache","Sedation","Somnolence","Dizziness","Nasoparyngitis"]}}}